US BioTek Laboratories said it is offering a new test, Monkeypox Diagnostic Testing, to help control the spread of the Monkeypox virus.
The test leverages a lesion swap specimen and uses real-time reverse transcription polymerase chain reaction (RT-PCR) testing to identify the Monkeypox virus, as suggested by the Centers for Disease Control and Prevention (CDC).
According to the company, the test will help individuals to know their Monkeypox infection status quickly.
US BioTek Laboratories CEO Jack Frausing said: “As we have seen in recent years, quantifying our viral statuses as quickly as possible can have huge impacts on our personal and public health.
“At US BioTek, we strive to offer our customers the testing they need to improve the lives of their patients. In the case of Monkeypox, we are doing so by offering test results in less than 24 hours.”
Monkeypox Diagnostic Testing will deliver results within 24 hours of receiving specimens
The test involves a simple collection method using a skin lesion swab and easy-to-read positive/negative report formats.
The firm said Monkeypox diagnostic testing is available to all practitioners with company accounts.
US BioTek Laboratories is engaged in developing testing methods that provide quality results with greater accuracy.
The company is focused on leveraging third-party peer-reviewed literature and the insights from its network of providers to develop evidence-based panels suitable for clinical use.
